Dublin City University
|As first author||5|
|As last author||103|
Sinéad T Aherne(12)
... and 116 others
These arethe12 unique sources for Martin Clynes's 208 publications. A single publication may appear in multiple sources. Click on a name or publication count to see the publications for a particular source.
|Ireland -> Dublin City University||178|
|Ireland -> Dublin City University -> PubMed||170|
|Ireland -> IT Tallaght||1|
|Ireland -> IT Tallaght -> PubMed||1|
|Ireland -> Maynooth University||30|
|Ireland -> Maynooth University -> PubMed||2|
|Ireland -> Royal College of Surgeons in Ireland||6|
|Ireland -> Royal College of Surgeons in Ireland -> PubMed||3|
|Ireland -> Trinity College Dublin||30|
|Ireland -> Trinity College Dublin -> PubMed||2|
|Ireland -> University College Cork||1|
|Ireland -> University College Cork -> PubMed||1|
A method of monitoring a breast cancer patient's response to treatment, or of detecting recurrence of breast cancer, the method comprising a step of assaying a plurality of samples obtained from the patient over a period of time for expression levels of a plurality of biomarkers including Cancer Antigen 15-3 (CA 15-3) and one of either Glutamate or 12-Hydroxyeicosatetraenoic acid (12-HETE), and detecting a change in expression levels of CA 15-3 and one (or both) of either Glutamate or 12-HETE over the time period, wherein detection of a decreased expression levels of CA 15-3 and one of either Glutamate or 12-HETE over the time period is indicative of a response to therapy and wherein detection of increased or stable expression levels of CA 15-3 and one of either Glutamate or 12-HETE over the time period is indicative of a non-response to breast cancer therapy.
A method for the inhibition, prevention or treatment of invasive/metastatic cancer in an individual in need thereof, comprises a step of treating the individual with an agent capable of attenuating the activity of protein selected from the group consisting of: STIPl
The invention relates to a method of screening patients to identify patients at risk of having a lung squamous cell carcinoma. A sample of serum from the individual is assayed for the abundance of a protein selected from the group consisting of: SEQUENCE ID NO'S: 1 to 11 relative for a control abundance for that protein, and the relative abundance obtained is correlated with risk of lung SCC cancer. The diagnosis may involve a single diagnostic variable or a panel of diagnostic variables. For each biomarker, relative abundance may be obtained by means of 2-DIGE separation and gel imaging. The samples are generally pre-treated to remove highly abundant proteins from the serum.
The present invention relates to markers indicative of invasion in cancers, particularly breast and lung carcinomas. These markers find use in the diagnosis/prognosis of invasion (metastasis) and may thus be useful in identification of suitable treatment regiment for patients. The markers may also be of use in identifying potential therapeutic agents or targets for the prevention or reduction of invasion in cancer patients.
The present invention provides, among other things, systems and methods for identifying genes and proteins that regulate and/or are indicative of cell phenotypes based on expression profiling analysis. The present invention further provides methods of manipulating identified genes and proteins to engineer improved cell lines.
The invention relates to a novel panel of mRNA markers that have potential as diagnostic, prognostic and/or predictive indicators of breast cancer. Members of this panel also have potential as novel therapeutic targets.
The present invention provides methods for systematically identifying genes and proteins and related pathways that maximize protein expression and secretion by expression profiling analysis. The present invention further provides methods for manipulating the identified genes and proteins to engineer improved cell lines.
Clicking through these tabs will give you a wealth of further insights into this expert through their commonly used topics, the evolution of their expertise, their collaborators and their publications.
Here is a quick breakdown of this expert's publication history
If this is the expert you have been looking for, simply click here to make contact.